Nanovaccine’s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy

Zhang, Lingxiao; Sun, Xia-mei; Jia, Yingbo; Liu, Xiao-Ge; Dong, Mingdong; Xu, Zhi Ping

doi:10.1016/j.nantod.2020.100923

Cited by 35 publications

(33 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…employed a classical “priming + boosting” vaccination strategy to investigate whether the change of vaccination route will affect the induction of anti-tumor immune responses (Fig. 12 a) [ 9 ]. In this study, four vaccine routes include twice i.v.…”

Section: Delivery Of Nanovaccines To Spleenmentioning

confidence: 99%

Section: Delivery Of Nanovaccines To Spleenmentioning

confidence: 99%

“…The potential reason may be due to the formation of vaccine depot at the injection site, which induces anti-tumor immune responses through a time–cost APCs recruitment and antigen delivery process (defined as depot effect) [ 6 – 8 ]. During this process, it takes around 3–7 days for vaccines to reach the highest accumulation in lymph node (LN), a period of time allows the tumor volume to increase by 8–10 times in mice [ 9 ]. Therefore, the imbalance between the slow immune induction and the rapid tumor proliferation is a key to limiting the efficacy of cancer immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

With the in-depth exploration on cancer therapeutic nanovaccines, increasing evidence shows that the poor delivery of nanovaccines to lymphoid organs has become the culprit limiting the rapid induction of anti-tumor immune response. Unlike the conventional prophylactic vaccines that mainly form a depot at the injection site to gradually trigger durable immune response, the rapid proliferation of tumors requires an efficient delivery of nanovaccines to lymphoid organs for rapid induction of anti-tumor immunity. Optimization of the physicochemical properties of nanovaccine (e.g., size, shape, charge, colloidal stability and surface ligands) is an effective strategy to enhance their accumulation in lymphoid organs, and nanovaccines with dynamic structures are also designed for precise targeted delivery of lymphoid organs or their subregions. The recent progress of these nanovaccine delivery strategies is highlighted in this review, and the challenges and future direction are also discussed. Graphical Abstract

show abstract

Section: Delivery Of Nanovaccines To Spleenmentioning

confidence: 99%

Section: Delivery Of Nanovaccines To Spleenmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Zhang combined primary intravenous immunization with subcutaneous booster immunization, which can induce a higher anti‐tumor immune response in a shorter time. [ 132 ] Hu reported on the preparation of an oral DNA tumor vaccine that can overcome the human body's natural immune barrier by modifying the surface of bacteria; [ 133 ] however, in general, intramuscular injection, intradermal injection, and subcutaneous injection are still the mainstream of tumor vaccination, especially for the treatment of cancers with poor accessibility. [ 134 ] The development of new vaccine delivery methods may be a direction for future research.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions

Zhai

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

To solve the problems of high toxicity and poor efficacy of existing tumor treatment methods, researchers have developed a variety of tumor immunotherapies. Among them, tumor vaccines activate antigen‐presenting cells and T lymphocytes upstream of the cancer‐immunity cycle are considered the most promising therapy to activate the immune system. Nanocarriers are considered the most promising tumor vaccine delivery vehicles, including polymer nanocarriers, lipid nanocarriers, inorganic nanocarriers, and biomimetic nanocarriers that have been developed for vaccine delivery. Based on the cascade reaction for tumor vaccines to exert their effects, this review summarizes the four key factors for the design and construction of nano‐tumor vaccines. The composition and functional characteristics of the corresponding preferred nanocarriers are illustrated to provide a reference for the development of effective tumor vaccines. Finally, potential challenges and perspectives are illustrated in the hope of improving the efficacy of tumor vaccine immunotherapy and accelerating the clinical transformation of next‐generation tumor vaccines.

show abstract

“…There might also be interdependence between these parameters. For instance, it was recently reported that a sequential intravenous priming vaccination followed by a later intradermal boost vaccination showed the best effects in providing antitumor immunity in mice, while simultaneous administration significantly worsened the outcome [95]. Apart from these practical aspects, the scientific challenges lie in the mapping of the type and number of the oxidative antigen modifications, the identification of optimal ROS cocktails for maximizing immunogenicity, the elucidation of putative APC receptors needed to recognize oxidized antigen, and the clarification of the role of the proteasomal and antigenpresenting machinery activity to stimulate cognate antigen recognition optimally in the host.…”

Section: Concept and Challenges Of Multi-ros-modified Autologous Tumor Vaccinesmentioning

confidence: 99%

ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

Clemen

Bekeschus

2021

Vaccines

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide. Today, the critical role of the immune system in tumor control is undisputed. Checkpoint antibody immunotherapy augments existing antitumor T cell activity with durable clinical responses in many tumor entities. Despite the presence of tumor-associated antigens and neoantigens, many patients have an insufficient repertoires of antitumor T cells. Autologous tumor vaccinations aim at alleviating this defect, but clinical success is modest. Loading tumor material into autologous dendritic cells followed by their laboratory expansion and therapeutic vaccination is promising, both conceptually and clinically. However, this process is laborious, time-consuming, costly, and hence less likely to solve the global cancer crisis. Therefore, it is proposed to re-focus on personalized anticancer vaccinations to enhance the immunogenicity of autologous therapeutic tumor vaccines. Recent work re-established the idea of using the alarming agents of the immune system, oxidative modifications, as an intrinsic adjuvant to broaden the antitumor T cell receptor repertoire in cancer patients. The key novelty is the use of gas plasma, a multi-reactive oxygen and nitrogen species-generating technology, for diversifying oxidative protein modifications in a, so far, unparalleled manner. This significant innovation has been successfully used in proof-of-concept studies and awaits broader recognition and implementation to explore its chances and limitations of providing affordable personalized anticancer vaccines in the future. Such multidisciplinary advance is timely, as the current COVID-19 crisis is inexorably reflecting the utmost importance of innovative and effective vaccinations in modern times.

show abstract

Nanovaccine’s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy

Cited by 35 publications

References 49 publications

Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy

Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy

Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions

ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

Contact Info

Product

Resources

About